A DNA double helix model (illustrative photo)
  • November 22, 2026
  • Anees
  • 0

A single infusion of an experimental gene-editing therapy cut “bad” LDL cholesterol by 52 percent, with the benefit still holding a full year after treatment — an early sign that one CRISPR treatment might one day replace a lifetime of daily pills.

Key Points

  • CRISPR cholesterol therapy — A one-time infusion of CTX310, a CRISPR-Cas9 therapy, cut LDL cholesterol by an average of 52.5% at the highest dose after one year.
  • Triglycerides fell by 47.8% and the target protein ANGPTL3 by 78.6% at the highest dose, in a 15-patient trial led by Cleveland Clinic.
  • The results, published in the New England Journal of Medicine, held steady for 12 months after a single intravenous infusion.
  • A separate group with severe high triglycerides saw a 63% reduction just 30 days after treatment, presented at the American Heart Association meeting.
  • The trial was tiny, open-label and had no placebo group, so the results are promising but early — the treatment has not been shown to prevent heart attacks.
A scientist working with a pipette in a laboratory (illustrative photo)

The treatment, called CTX310, uses CRISPR-Cas9 to switch off a gene called ANGPTL3 in the liver. CTX310 is delivered inside a tiny fat particle that carries the editing machinery into liver cells, where it disables the gene in a single intravenous infusion, given at doses from 0.1 to 0.8 milligrams per kilogram of body weight after pre-treatment with corticosteroids and antihistamines.

The trial enrolled 15 adults whose cholesterol and triglyceride problems had resisted standard medicines, all of them already on the maximum tolerated doses of lipid-lowering drugs. At the highest dose, researchers measured average one-year reductions of 78.6 percent in the ANGPTL3 protein, 52.5 percent in LDL cholesterol, 47.8 percent in triglycerides and 37.2 percent in apolipoprotein B, with no dose-limiting toxic effects or serious treatment-related adverse events recorded. “The durability of the lipid-lowering effect was impressive,” said Cleveland Clinic cardiologist Luke Laffin, the study’s co-first author.

A second group, and a second drug

The one-year results, published in the New England Journal of Medicine on 28 August 2026, were followed by new data presented at the American Heart Association’s annual meeting in Chicago in November. In a separate Phase 1b group of 10 adults with severe hypertriglyceridemia, a single infusion cut triglycerides by an average of 63 percent at 30 days, with reductions reaching up to 85 percent. The findings have put CTX310 at the front of a small field of one-time gene editors for cholesterol. A rival treatment, VERVE-102 from Verve Therapeutics — now part of Eli Lilly — uses a different editing technique to switch off the PCSK9 gene and has cut LDL by up to 62 percent in 35 patients.

Drugmakers have spent years mimicking the ANGPTL3 effect with antibodies and RNA-silencing drugs that require repeat dosing. A one-time edit, if it holds up, would in principle only need to be done once — which is why cardiologists are watching these trials so closely. But the researchers themselves stress the limits: with only 15 participants, the trial could easily miss uncommon problems, and one year offers limited information about effects that may develop slowly. The study was funded by CTX310’s maker, CRISPR Therapeutics, and it had no placebo group, so it cannot rule out other explanations for the changes.

What happens next

Cleveland Clinic said a Phase 1b trial is expected to begin soon, giving all participants the same higher dose and focusing on narrower groups of patients, with US sites included. Any path to approval would still require larger, randomised, placebo-controlled trials measuring actual heart attacks and strokes — not just cholesterol numbers — a process likely to take years. For patients whose cholesterol cannot be controlled with today’s medicines, the message is one of cautious hope: a single treatment that keeps working for a year is a genuine milestone, but it is a first step, not a finished medicine.

For background on other recent trial results, see our report on Merck Cancer Drug Prolongs Survival in Advanced Stomach and Oesophageal Cancers, and on Viagra-Like Pill Slows Alzheimer’s Decline by 31% in Major Trial. More in our Health section.

Sources: Good News Network, “First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy” (https://www.goodnewsnetwork.org/first-human-trial-to-slash-bad-cholesterol-by-50pt-with-one-crispr-injection/); Knowridge, “One gene-editing treatment lowers bad cholesterol for a full year” (https://knowridge.com/2026/11/one-gene-editing-treatment-lowered-bad-cholesterol-for-a-full-year/)

Leave a Reply

Your email address will not be published. Required fields are marked *